The role of T cells in systemic lupus erythematosus: An update

Current Opinion in Rheumatology

Volumn 26, Issue 5, 2014, Pages 493-501

  Konya, Christine ^a   Paz, Ziv ^a   Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Interleukin 2; systemic lupus erythematosus; T cells

Indexed keywords

DNA; INTERLEUKIN 2; MICRORNA; T LYMPHOCYTE RECEPTOR; HISTONE; LYMPHOCYTE ANTIGEN RECEPTOR;

AUTOIMMUNITY; CYTOKINE PRODUCTION; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; IMMUNE RESPONSE GENE; LIPID RAFT; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ANIMAL; BIOLOGICAL MODEL; CELL MEMBRANE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HELPER CELL; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE MICRODOMAINS; MICRORNAS; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84905495798     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000082     Document Type: Review

References (88)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110-2121.
2. Paz Z, Tsokos GC. New therapeutics in systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25:297-303.
3. Enyedy EJ, Nambiar MP, Liossis SN, et al. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44:1114-1121.
4. Nambiar MP, Enyedy EJ, Fisher CU, et al. Abnormal expression of various molecular forms and distribution of T cell receptor zeta chain in patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:163-174.
5. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3- mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus: deficient expression of the T cell receptor zeta chain. J Clin Invest 1998; 101:1448-1457.
6. Nambiar MP, Fisher CU, Kumar A, et al. Forced expression of the Fc receptor gamma-chain renders human T cells hyperresponsive to TCR/CD3 stimulation. J Immunol 2003; 170:2871-2876.
7. Nambiar MP, Fisher CU, Warke VG, et al. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/ CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:1948-1955.
8. Deng GM, Liu L, Bahjat FR, et al. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010; 62:2086-2092.
9. Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011; 13:207.
10. Moulton VR, Tsokos GC. Alternative splicing factor/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex. J Biol Chem 2010; 285:12490-12496.
11. Moulton VR, Grammatikos AP, Fitzgerald LM, Tsokos GC. Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proc Natl Acad Sci U S A 2013; 110:1845-1850.
12. Jury EC, Kabouridis PS, Flores-Borja F, et al. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004; 113:1176-1187.
13. Krishnan S, Nambiar MP, Warke VG, et al. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 2004; 172:7821-7831.
14. Kabouridis PS, Jury EC. Lipid rafts and T-lymphocyte function: implications for autoimmunity. FEBS Lett 2008; 582:3711-3718.
15. Deng GM, Tsokos GC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol 2008; 181:4019-4026.
16. Kidani Y, Bensinger SJ. Lipids rule: resetting lipid metabolism restores T cell function in systemic lupus erythematosus. J Clin Invest 2014; 124:482-485.
17. Jain J, Loh C, Rao A. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 1995; 7:333-342.
18. Tenbrock K, Tsokos GC. Transcriptional regulation of interleukin 2 in SLE T cells. Int Rev Immunol 2004; 23:333-345.
19. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69:1388-1392.
20. Linker-Israeli M, Bakke AC, Kitridou RC, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130:2651-2655.
21. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009; 30:204-217.
22. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579-2588.
23. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+T cell regulatory functions. J Immunol 2007; 178:271-279.
24. Marks-Konczalik J, Dubois S, Losi JM, et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000; 97:11445-11450.
25. Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115:996-1005.
26. Rauen T, Benedyk K, Juang YT, et al. A novel intronic cAMP response element modulator (CREM) promoter is regulated by activator protein-1 (AP-1) and accounts for altered activation-induced CREM expression in T cells from patients with systemic lupus erythematosus. J Biol Chem 2011; 286:32366-32372.
27. Hedrich CM, Rauen T, Tsokos GC. cAMP-responsive element modulator (CREM) alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J Biol Chem 2011; 286:43429-43436.
28. Ichinose K, Juang YT, Crispin JC, et al. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin- dependent protein kinase type IV. Arthritis Rheum 2011; 63:523-529.
29. Crispin JC, Apostolidis SA, Finnell MI, Tsokos GC. Induction of PP2A Bbeta, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2011; 108:12443-12448.
30. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240-246.
31. Kyttaris VC, Juang YT, Tenbrock K, et al. Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 2004; 173:3557-3563.
32. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98:826-837.
33. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97:2063-2073.
34. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48:719-727.
35. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13:391-397.
36. Gorelik G, Richardson B. Key role of ERK pathway signaling in lupus. Autoimmunity 2010; 43:17-22.
37. Gorelik G, Fang JY, Wu A, et al. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazineinduced lupus. J Immunol 2007; 179:5553-5563.
38. Yasuda S, Stevens RL, Terada T, et al. Defective expression of Ras guanyl nucleotide-releasing protein 1 in a subset of patients with systemic lupus erythematosus. J Immunol 2007; 179:4890-4900.
39. Deng C, Kaplan MJ, Yang J, et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001; 44:397-407.
40. Oelke K, Lu Q, Richardson D, et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 2004; 50:1850-1860.
41. Li Y, Harada T, Juang YT, et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007; 178:1938-1947.
42. Biswas PS, Gupta S, Chang E, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest 2010; 120:3280-3295.
43. Fujita Y, Fujii T, Mimori T, et al. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice. J Immunol 2014; 192:979-984.
44. Yu Y, Liu Y, Shi FD, et al. Cutting edge: leptin-induced RORgammat expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol 2013; 190:3054-3058.
45. Crispin JC, Tsokos GC. Human TCR-alpha beta+ CD4- CD8- T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol 2009; 183:4675-4681.
46. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181:8761-8766.
47. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 2009; 113:3027-3030.
48. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989; 143:103-112.
49. Hedrich CM, Rauen T, Crispin JC, et al. cAMP-responsive element modulator alpha (CREMalpha) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease. J Biol Chem 2013; 288:31880-31887.
50. Hedrich CM, Crispin JC, Rauen T, et al. cAMP responsive element modulator (CREM) alpha mediates chromatin remodeling of CD8 during the generation of CD3+ CD4- CD8- T cells. J Biol Chem 2014; 289:2361-2370.
51. Dean GS, Anand A, Blofeld A, et al. Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: production of IL-4. Lupus 2002; 11:501-507.
52. Mehal WZ, Crispe IN. TCR ligation on CD8+ T cells creates double-negative cells in vivo. J Immunol 1998; 161:1686-1693.
53. Anand A, Dean GS, Quereshi K, et al. Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus 2002; 11:493-500.
54. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485-517.
55. Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1472-1483.
56. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009; 183:3160-3169.
57. Steinmetz OM, Turner JE, Paust HJ, et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol 2009; 183: 4693-4704.
58. Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008; 9:1297-1306.
59. Rauen T, Hedrich CM, Juang YT, et al. cAMP-responsive element modulator (CREM) alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem 2011; 286:43437-43446.
60. Koga T, Hedrich CM, Mizui M, et al. CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance. J Clin Invest 2014; 124:2234-2245.
61. Yang X, Yang J, Chu Y, et al. T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PloS One 2014; 9:e88441.
62. Yang X, Yang J, Chu Y, et al. T follicular helper cells mediate expansion of regulatory B cells via IL-21 in Lupus-prone MRL/lpr mice. PloS One 2013; 8:e62855.
63. Simpson N, Gatenby PA, Wilson A, et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum 2010; 62:234-244.
64. Futatsugi-Yumikura S, Matsushita K, Fukuoka A, et al. Pathogenic Th2-type follicular helper T cells contribute to the development of lupus in Fas-deficient mice. Int Immunol 2014; 26:221-231.
65. Dong W, Zhu P, Wang Y, Wang Z. Follicular helper T cells in systemic lupus erythematosus: a potential therapeutic target. Autoimmun Rev 2011; 10:299-304.
66. van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007; 2007:89017.
67. Ochs HD, Gambineri E, Torgerson TR. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res 2007; 38:112-121.
68. Bonelli M, Savitskaya A, von Dalwigk K, et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008; 20:861-868.
69. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008; 17:289-294.
70. Iikuni N, Lourenco EV, Hahn BH, La Cava A. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol 2009; 183:1518-1522.
71. Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009; 183:6346-6358.
72. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009; 10:373-379.
73. Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol 1998; 10:690-696.
74. Costa-Reis P, Sullivan KE. Genetics and epigenetics of systemic lupus erythematosus. Curr Rheumatol Rep 2013; 15:369.
75. Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006; 176:7143-7147.
76. Kaplan MJ, Deng C, Yang J, Richardson BC. DNA methylation in the regulation of T cell LFA-1 expression. Immunol Invest 2000; 29:411-425.
77. Coit P, Jeffries M, Altorok N, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferonregulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2013; 43:78-84.
78. Absher DM, Li X, Waite LL, et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 2013; 9:e1003678.
79. Sunahori K, Juang YT, Kyttaris VC, Tsokos GC. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. J Immunol 2011; 186:4508-4517.
80. Zhang Y, Zhao M, Sawalha AH, et al. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 2013; 41:92-99.
81. Hu N, Qiu X, Luo Y, et al. Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol 2008; 35:804-810.
82. Mishra N, Reilly CM, Brown DR, et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111:539-552.
83. Liu A, La Cava A. Epigenetic dysregulation in systemic lupus erythematosus. Autoimmunity 2014; 47:215-219.
84. Amarilyo G, La Cava A. miRNA in systemic lupus erythematosus. Clin Immunol 2012; 144:26-31.
85. Pan W, Zhu S, YuanM, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 2010; 184:6773-6781.
86. Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011; 70:1496-1506.
87. Sui W, Liu F, Chen J, et al. Microarray technology for analysis of microRNA expression in renal biopsies of lupus nephritis patients. Methods Mol Biol 2014; 1134:211-220.
88. Davis TE, Kis-Toth K, Tsokos GC. A114: methylprednisolone-induced inhibition of miR-155 expression increases SOCS1-driven suppression of cytokine signaling. Arthritis Rheumatol 2014; 66 (Suppl 11):S151.